Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 343

1.

Salivary Gland Ultrasonography as a Diagnostic Tool for Secondary Sjögren Syndrome in Rheumatoid Arthritis.

Das S, Huynh D, Yang H, Ceponis A, Kavanaugh A.

J Rheumatol. 2015 May 1. pii: jrheum.141149. [Epub ahead of print]

PMID:
25934827
2.

EAAT and Xc- Exchanger Inhibition Depletes Glutathione in the Transformed Human Lens Epithelial Cell Line SRA 01/04.

Langford MP, Redens TB, Liang C, Kavanaugh AS, Texada DE.

Curr Eye Res. 2015 Apr 21:1-10. [Epub ahead of print]

PMID:
25897760
3.

Advances in use of immunomodulatory agents-a rheumatology perspective.

Her M, Kavanaugh A.

Nat Rev Gastroenterol Hepatol. 2015 Apr 21. doi: 10.1038/nrgastro.2015.65. [Epub ahead of print] Review.

PMID:
25895821
4.

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG.

J Eur Acad Dermatol Venereol. 2015 Apr 16. doi: 10.1111/jdv.13150. [Epub ahead of print]

PMID:
25885420
5.

A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.

Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G.

PLoS One. 2015 Apr 8;10(4):e0123582. doi: 10.1371/journal.pone.0123582. eCollection 2015.

6.

Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations.

Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ.

J Rheumatol. 2015 Apr 1. pii: jrheum.140312. [Epub ahead of print]

PMID:
25834212
7.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

Busa S, Kavanaugh A.

Expert Opin Drug Saf. 2015 Jun;14(6):979-85. doi: 10.1517/14740338.2015.1031743. Epub 2015 Mar 31.

PMID:
25827658
8.

On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.

Gulati AM, Semb AG, Rollefstad S, Romundstad PR, Kavanaugh A, Gulati S, Haugeberg G, Hoff M.

Ann Rheum Dis. 2015 Mar 26. pii: annrheumdis-2014-206824. doi: 10.1136/annrheumdis-2014-206824. [Epub ahead of print]

PMID:
25814652
9.

Patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy demonstrate less radiographic progression: Results through 5 years of the randomized, placebo-controlled, GO-REVEAL study.

Kavanaugh A, van der Heijde D, Beutler A, Gladman D, Mease P, Krueger GG, McInnes IB, Helliwell P, Coates LC, Xu S.

Arthritis Care Res (Hoboken). 2015 Mar 16. doi: 10.1002/acr.22576. [Epub ahead of print]

PMID:
25779603
10.

Certolizumab pegol for the treatment of psoriatic arthritis.

Hansen RB, Kavanaugh A.

Expert Rev Clin Immunol. 2015 Mar;11(3):307-18. doi: 10.1586/1744666X.2015.1009897. Epub 2015 Feb 5.

PMID:
25651776
11.

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.

J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15.

12.

Concepts of pathogenesis and emerging treatments for inflammatory arthritis.

van Laar JM, Kavanaugh A.

Best Pract Res Clin Rheumatol. 2014 Aug;28(4):537-8. doi: 10.1016/j.berh.2014.11.001. No abstract available.

PMID:
25481547
13.

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.

Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, Etzel CJ, Cox V, Yoshida K, Reed GW, Solomon DH.

Ann Rheum Dis. 2015 Jun;74(6):1150-5. doi: 10.1136/annrheumdis-2014-206435. Epub 2014 Dec 3.

PMID:
25471471
14.

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS.

Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.

15.

Proceedings from the American College of Rheumatology Reproductive Health Summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases.

Kavanaugh A, Cush JJ, Ahmed MS, Bermas BL, Chakravarty E, Chambers C, Clowse M, Curtis JR, Dao K, Hankins GD, Koren G, Kim SC, Lapteva L, Mahadevan U, Moore T, Nolan M, Ren Z, Sammaritano LR, Seymour S, Weisman MH.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):313-25. doi: 10.1002/acr.22516. No abstract available.

PMID:
25385050
16.

Optimisation of assessment for rheumatic diseases in clinical trials, observational studies and routine clinical care.

Pincus T, Braun J, Kavanaugh A, Smolen JS.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-1. Epub 2014 Oct 30. No abstract available.

PMID:
25365080
17.

Treatments for nail psoriasis: a systematic review by the GRAPPA Nail Psoriasis Work Group.

Armstrong AW, Tuong W, Love TJ, Carneiro S, Grynszpan R, Lee SS, Kavanaugh A.

J Rheumatol. 2014 Nov;41(11):2306-14. doi: 10.3899/jrheum.140881.

PMID:
25362716
18.

Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA.

Coates LC, Kavanaugh A, Ritchlin CT; GRAPPA Treatment Guideline Committee.

J Rheumatol. 2014 Nov;41(11):2273-6. doi: 10.3899/jrheum.140875.

PMID:
25362710
19.

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.

Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME.

J Rheumatol. 2014 Nov;41(11):2120-8. doi: 10.3899/jrheum.140238. Epub 2014 Sep 15.

PMID:
25225285
20.

Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D.

Arthritis Rheumatol. 2014 Dec;66(12):3255-64. doi: 10.1002/art.38851.

PMID:
25223724
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk